LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $112.60.

LMAT has been the topic of several research reports. Citizens Jmp boosted their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 6th. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings upgraded LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 20th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th.

LeMaitre Vascular Stock Up 1.9%

Shares of NASDAQ LMAT opened at $93.95 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The stock has a market capitalization of $2.15 billion, a PE ratio of 34.67, a P/E/G ratio of 2.56 and a beta of 0.54. LeMaitre Vascular has a one year low of $79.00 and a one year high of $118.01. The business’s fifty day moving average price is $102.79 and its 200-day moving average price is $96.36.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities research analysts anticipate that LeMaitre Vascular will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.1%. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider directly owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 54,453 shares of company stock worth $5,906,174 in the last quarter. 7.40% of the stock is owned by company insiders.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sound Income Strategies LLC grew its position in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the first quarter worth $32,000. MAI Capital Management purchased a new stake in shares of LeMaitre Vascular in the third quarter worth $38,000. Geneos Wealth Management Inc. boosted its stake in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the second quarter valued at $47,000. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.